Morepen Laboratories reports Q4 FY25 consolidated PAT at Rs. 20.31 Cr
The company has posted net profit of Rs. 118.01 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs. 118.01 crores for the Financial Year ended March 31, 2025
Scores highest PAT of Rs. 118 crore in FY25
Launched in Thailand, the ASEAN hub, marking an early entry into the fast-growing combination therapy market (DPP-4 and SGLT-2 inhibitor combination) with strong potential for market leadership
The company has posted net profit of Rs. 338.55 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs. 1,767.63 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs. 55.36 crores for the Financial Year ended March 31, 2025
ISPP will analyze health systems across states, identifying scalable models and actionable insights to strengthen India's healthcare delivery
The company has posted net profit of Rs.168.16 crores for the Financial Year ended March 31, 2025
This marks yet another milestone in our series of successful audits over the past year
Integrated facility to deliver end-to-end, customized workflows across life sciences, diagnostics, and applied markets
Subscribe To Our Newsletter & Stay Updated